2025 annual financial data
Sutro Biopharma 2025 Operating cash flow margin
Direct answer
Operating cash flow margin was -172.94%.
Operating income was -104.95M USD and net income was -191.09M USD.
Operating cash flow was -177.23M USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 102.48M USD
- Operating income
- -104.95M USD
- Net income
- -191.09M USD
- Operating cash flow
- -177.23M USD